Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06424236 · ClinicalTrials.gov registry record · Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT06424236 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 73 participants.
The verdict
NCT06424236, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Interventions
- DRUG Gantenerumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06424236
The ClinicalTrials.gov registry entry for NCT06424236 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gantenerumab is the first listed.
NCT06424236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06424236 about?
NCT06424236 is a clinical study titled "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation". The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical imp...
What is the current status of trial NCT06424236?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2020-06-03. Estimated completion is 2023-11-13.
What interventions are being tested in trial NCT06424236?
The interventions under investigation include: Gantenerumab (DRUG).
Who is sponsoring clinical trial NCT06424236?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.